CD8A and systemic lupus erythematosus: Given the crucial roles of not only B cells but also T cells, specifically granzyme K + CD8 T cells in the pathogenesis of SLE [6, 7], tacrolimus was proven to be effective and safe to use as an induction and maintenance therapy [8–10] This has led to its widespread application as a main treatment option for SLE [1].